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EnteropathyBackground: Primary sclerosing cholangitis (PSC) and autoimmune sclerosing cholangitis (AISC) are related, but
distinct chronic liver diseases. PSC is associated with a high prevalence of ulcerative colitis while the intestinal
inﬂammation associated with AISC is less well characterised.
Aims: To assess and contrast aspects of intestinal inﬂammation in patients with AISC and PSC and compare the
clinical features with those of patients with ulcerative colitis and Crohn's disease.
Methods: 23 and 22 patients with AISC and PSC, respectively, underwent review of colonoscopy and biopsy ﬁnd-
ings, capsule enteroscopy and assessment of clinical and inﬂammatory (faecal calprotectin) disease activity,
which was compared with that of patients with ulcerative colitis and Crohn's disease (n = 55 each).
Findings: Five and 6 patients with AISC and PSC, respectively, had normal colonoscopy and faecal calprotectin
levels of 34.4 ± 8.3 and 39.7 ± 8.4 μg/g, respectively (normal b50 μg/g), whereas 18 and 16, respectively, had
identical variably severe, right sided colitis with frequent rectal sparing, consistent with ulcerative colitis.
Mean (±SD) faecal calprotectin levels did not differ signiﬁcantly (p N 0.05) between patients with intestinal in-
ﬂammation in AISC (588 ± 549 μg/g), PSC (421 ± 351 μg/g), ulcerative colitis (501 ± 656 μg/g) or Crohn's dis-
ease (476 ± 571 μg/g). Capsule enteroscopy showed that 7 of 18 (39%) (p b 0.03) of those with AISC had small
bowel mucosal breaks whereas no patient with PSC had these ﬁndings.
Interpretation: Collectively these ﬁndings lend support to the suggestion that the chronic inﬂammatory bowel
disease associatedwith PSC and in particular AISCmay represent a distinct nosologic entity different from classic
ulcerative colitis and Crohn's disease.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The association between hepatobiliary disease and inﬂammatory
bowel disease (IBD) is well documented (Bjarnason et al., 1995). It is
most obviously illustrated in thehighprevalence (70–90%)of colitis in pa-
tients with primary sclerosing cholangitis (PSC) (Saich and Chapman,
2008), which falls within the spectrum of ulcerative colitis (UC) (Saich
and Chapman, 2008). Conversely PSC is an extra-intestinal manifestation
of IBD with approximately 5% and 3.5% of patients with UC and Crohn's
disease (CD), respectively, developing the disease (Saich and Chapman,
2008; Schrumpf et al., 1980; Olsson et al., 1991). However the colitis in
patients with and without PSC differs. The former is characteristicallyrology and Colorectal Surgery,
.
on).
. This is an open access article underassociated with a more indolent clinical course and a more severe proxi-
mal colonic involvementwith rectal sparing (60–70%) (Loftus et al., 2005)
and there is an unexplained higher incidence of colorectal cancer (Shetty
et al., 1999; Soetikno et al., 2002). Collectively these observations suggest
that PSC-colitis may represent a distinct disease entity from classic UC
(Loftus et al., 2005; Lundqvist and Broomé, 1997).
Patients with PSCmay have clinical, biochemical and serological fea-
tures resembling other liver diseases, especially that of autoimmune
hepatitis (Vogel et al., 2002), the latter having a lower prevalence of co-
litis (about 16%) (Saich and Chapman, 2008). Furthermore autoimmune
sclerosing cholangitis (AISC) (Floreani et al., 2005), proposed as a dis-
tinctive disease entity in 2001 (Gregorio et al., 2001), has clinical over-
lap features with PSC and autoimmune hepatitis, but patients are
typically a younger age at presentation and the autoimmune serology
differs (Gregorio et al., 2001; Bogdanos et al., 2008). The colitis of AISC
has not been examined in detail.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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AISC and compared the ﬁndings with that seen in patients with PSC-
associated colitis. Intestinal inﬂammatory activity and clinical relapse
rates were compared with that of patients with classic IBD.
2. Materials & Methods
The liver unit at King's CollegeHospital runs a transition clinic for ad-
olescents and young adults with chronic liver disease, whereby care is
transferred from paediatric to adult liver and gastroenterology services.
Such patients undergo a protocol-driven evaluation and assessment to
determine the presence, severity, type and extent of intestinal
inﬂammation. The diagnosis of AISC (Gregorio et al., 2001) and PSC
had been based on standardised criteria following consideration of con-
ventional clinical features and a number of test results, including a panel
of auto-antibodies, endoscopic retrograde or magnetic resonance
cholangiopancreatography (all patients had one or the other, ranging
in number from 1 to 17) and liver biopsy (all patients had a liver biopsy,
ranging in number from 1 to 7) that had been assessed by the Liver Unit
histopathologists.
During the period of January 2009 to July 2013 twenty three patients
with AISC were transferred to the King's IBD adult clinic. Five of these
did not have colitis on previous colonoscopy with biopsy. Their demo-
graphic details are shown in Table 1.
During the same time, 22 patients with PSC with and without colitis
(16 and 6, respectively) were seen in the IBD clinic. Their demographic
details are shown in Table 1.
Patients with AISC and PSC and a diagnosis of CD (n= 4) were spe-
ciﬁcally excluded from this study, as were patients that had undergone
colectomy.
None of the patients with liver disease had received topical therapy
for colitis prior to colonoscopy and all had mild to moderate (≤6 point
scores) clinical disease activity as assessed by the Truelove–Witts
criteria (Truelove and Witts, 1955). Liver biochemical proﬁles showed
all but 3 to have stabile or quiescent liver disease. These 3 (one with
AISC and 2 with PSC) had jaundice with raised bilirubin and raised
transaminase levels, but their other results did not differ or stand out
in any major way from the other patients.
Clinical notes were reviewed along with a face-to-face consultation.
Each patient underwent routine laboratory tests, faecal calprotectin
(providing a quantitative measure of intestinal inﬂammation) and
video capsule enteroscopy as part of a standardised protocol.
Control groups for the faecal calprotectin studies comprised 55 UC
patients (26 (47%) with procto-sigmoiditis, 20 (36%) with left sided co-
litis and 9 (16%)with pan-colitis) and 55with CD (34 (62%)with and 21Table 1
Demographic details of the patients with AISC, PSC, UC and CD.
AISC AISC + IBD PS
Number 5 18 6
Age at diagnosis (years)⁎ 10.8 ± 1.7 12.3 ± 1.0 41
Age at study (years)⁎ 18.0 ± 0.8 19.4 ± 0.6 47
Duration of colitis⁎ 4.5 ± 0.9
Treatment
Prednisolone (2.5–10 mg/day) 3/5 (60%) 14/18 (78%) 5/
Azathioprine (25–125 mg) 3/5 (60%) 16/18 (89%) 4/
Ursodeoxycholic acid (UDCA) 4/5 (80%) 17/18 (94%) 6/
Tacrolimus 1/5 (20%) 5/18 (28%) 0/
Mycophenolate 0/5 (0%) 1/18 (6%) 0/
Mesalazine 0/5 (0%) 15/18 (83%) 0/
Faecal calprotectin (microg/g)⁎ 34.4 ± 8.3 588 ± 549 39
AISC = Autoimmune sclerosing cholangitis.
PSC = Primary sclerosing cholangitis.
UC = Ulcerative colitis.
UDCA= Ursodeoxycholic acid.
⁎ Mean ± SD.
⁎⁎ Azathioprine dose in UC and Crohn's disease ranged from 100 to 225 mg (2–21/2 mg per(38%) without small bowel involvement). These were identiﬁed in the
IBD clinics as routine follow-up or ‘walk-ins’ at King's College Hospital
appointments, during the same time period. They were chosen on the
basis that they had no more than moderate clinical disease activity;
4–≤6 point score for UC (Truelove and Witts, 1955), and Harvey–
Bradshaw disease score b16 for CD (Harvey and Bradshaw, 1980). All
patients attending these clinics have a faecal calprotectin measurement
as part of their standard of care one week prior to clinic attendance.
Their demographic details are shown in Table 1.
2.1. Colonoscopy and Histopathology
The colonoscopy reports, images and biopsies from the patientswith
AISC and PSCwere re-examined (colonoscopywasnot clinically indicat-
ed or performed at the time of study). The histopathologic examination
was carried out without knowledge of the underlying disease and the
diagnosis of colitis was made using conventional criteria.
2.2. Faecal Calprotectin
Faecal calprotectin test was carried out as previously described
(Maiden et al., 2005), using an ELISA method (Buhlmann Laboratories
AG, Schonenbuch, Switzerland). The upper normal value for the test
(b50 μg/g) is based on over 250 normal subjects (Department of Clinical
Biochemistry at King's College Hospital).
2.3. Capsule Enteroscopy
Small bowel capsule enteroscopy was carried out using PillCam SB1
or 2 (Given Imaging Ltd.; Yoqneam, Israel) and processed as previously
described (Maiden et al., 2005; 2007). The digital image stream was
assessed and interpreted by two experienced staff. The local database
includes studies on over 200 healthy volunteer controls.
There are no widely accepted criteria for presenting capsule
enteroscopy results, but for the purpose of this study we combined le-
sions that encompassed erosions and ulcers into a single group “muco-
sal breaks” as we and other groups have done previously (Maiden et al.,
2005; 2007; Goldstein et al., 2005; 2007). The reason for not
distinguishing between the two is that the images do not allow a reli-
able assessment of the depth of the lesions, which is a prerequisite for
a reliable diagnosis of an ulcer.
These data were collected as a part of an audit of gastroenterology
services, approved by the King's College Hospital Clinical Effectiveness
Department. All patients gave informed written consent to video cap-
sule enteroscopy.C PSC + IBD UC Crohn's disease
16 55 55
.7 ± 5.9 30.9 ± 2.9 38.6 ± 17.1 33.2 ± 15.9
.5 ± 5.6 42.9 ± 3.7 44.6 ± 18.6 38.7 ± 17.2
8.2 ± 1.7
6 (83%) 11/16 (69%) 0 1/55 (1.8%)
6 (67%) 14/16 (88%) 11/55 (20%)⁎⁎ 16/55 (29%)⁎⁎
6 (100%) 15/16 (94%) 0 0
6 (0%) 9/16 (56%) 0 0
6 (0%) 3/16 (19%) 0 0
6 (0%) 13/16 (81%) 49/55 (89%) 32/55 (58%)
.7 ± 8.4 428 ± 351 501 ± 656 476 ± 571
kg bodyweight).
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Patients with AISC were signiﬁcantly younger than those with PSC
and IBD (Table 1). Immunosuppressants and ursodeoxycholic acid
were commonly used in the liver patients, but not in the IBD groups,
but otherwise the demographic details of patients with AISC and PSC
at the time of study did not differ signiﬁcantly.
3.1. Colonoscopy and Histopathology in AISC and PSC
Five and 6 patients with AISC and PSC, respectively, had normal co-
lonoscopy with biopsy. The rest had undergone a number of colonosco-
pies (AISC= 2 to 5 and PSC 2–11) at various stages of their disease. The
macroscopic appearances did not differ between the two groups and
ranged from that of classical ulcerative colitis (recto-sigmoid to pan-
colitis) to that of right-sided ulcerative colitis with rectal sparing. The
macroscopic rectal sparing was variable given an individual and the ac-
tivity of disease, but overall at some time evident in 70%.
The microscopic ﬁndings of the colonic mucosa were identical be-
tween patients with AISC and PSC. The inﬂammationwas almost invari-
ably more pronounced in the right colon and while there were no
features suggestive of CD (granulomas, giant cells, ﬁssures, transmural
inﬂammation), the microscopic changes (branching of glands, goblet
cell depletion, cryptitis, etc.) that had suggested a diagnosis of UC
were oftenmild, somuch so as to give the overall impression of a chron-
ic non-speciﬁc indeterminate colitis although clearly favouring UC over
CD.
3.2. Faecal Calprotectin
Table 1 shows that the faecal calprotectin concentrations from the
patients without colitis were normal while those from patients with
AISC- and PSC-colitis, UC and CD were increased and did not differ sig-
niﬁcantly (p N 0.05) between the groups.
3.3. Capsule Enteroscopy
The 11 patients with AISC and PSC without colitis all had normal
small bowel capsule studies.
Seven of the capsule enteroscopy studies in the patients with AISC
were abnormal with mucosal breaks (ranged in number from 3 to
over 20) most pronounced in the distal ileum. Representative images
are shown in Fig. 1. There were also some changes indicative of inﬂam-
mation and although difﬁcult to quantitate, theseweremild, patchy and
equally found in the mid small bowel and in the distal ileum.
All of the capsule enteroscopy studies in the PSC patients were nor-
mal, apart fromone thatwas suggestive of backwash ileitis withoutmu-
cosal breaks and a further 3 that had verymild inﬂammatory changes in
themid small bowel, consistent with small bowel bacterial overgrowth.
4. Discussion
This study shows that patients with AISC have a colitis that is indis-
tinguishable from that seen in patients of PSC, which, by convention,
represents UC (Saich and Chapman, 2008; Loftus et al., 2005). Certain
clinical and histopathology aspects of the disease conform towhat is al-
ready described, however, we have also demonstrated that over a third
of patients with AISC have small bowel ﬁndings similar to that seen in
CD. Thus, placing these colitides under the umbrella of UC may need
revision.
In this report, all patients with AISC and PSC had initially been diag-
nosed with liver disease prior to the diagnosis of colitis. The colonoscopic
and histopathologic features of the colitis associated with AISC and PSC
conforms to that already described (Saich and Chapman, 2008; Loftus
et al., 2005). As colonoscopies were carried out at varying times
and prior to this study it is not possible to correlate the functional(calprotectin) and morphological (colonic biopsies) inﬂammatory activi-
ty in these patients. Most studies show a good correlation between levels
of faecal calprotectin and intestinal inﬂammation in patients with UC
(Roseth et al., 1999; Schoepfer et al., 2009; Sipponen et al., 2008a) and
somewhat more variable, albeit signiﬁcant, in CD (Sipponen et al.,
2008b; D'Incà et al., 2007; Costa et al., 2003; Vieira et al., 2009). The histo-
pathology features in the colitis associated with AISC and PSC are less se-
vere than in classical IBD, yet, these patients have comparable levels of
intestinal inﬂammation as assessed by faecal calprotectin. This apparent
discrepancy may be due to the fact that the inﬂammation was predomi-
nantly right sided in AISC and PSC and thus not associated with the com-
mon symptoms of proctitis, evident in patients with classic ulcerative
colitis, and theymay hence have been ‘undertreated’. Furthermore histol-
ogy represents a static picture whereas faecal calprotectin levels repre-
sent the total ﬂux of neutrophils entering the bowel over time. The
speed by which neutrophils pass through the colonic mucosa differs
from disease to disease depending on the site of the principal neutrophil
chemoattractant (Teahon and Bjarnason, 1993), and if particularly rapid
may not be so evident on biopsy.
A most signiﬁcant ﬁnding is that of approximately one third of the
patients with AISC having mucosal breaks on capsule enteroscopy. A
possible confounding factor, however, is that these patients were fre-
quently on immunosuppressive agents that have been implicated in
small bowel damage (Gabe et al., 1998; Bjarnason et al., 2004; 2006), al-
though if thiswas the case then this should have been equally evident in
PSC as they were receiving the same drugs.
Capsule enteroscopy images of mucosal breaks (erosions and ul-
cers) are not pathognomonic for any disease and have numerous
causes including use of NSAIDs, cocaine, certain chemotherapeutic
agents and are also described in patients with HIV, CD, Behçet's syn-
drome, spondyloarthropathy and radiation enteropathy (Bjarnason
et al., 2006; Oette et al., 2009). Most of these can be and were exclud-
ed as a cause for the small bowel ﬁndings in AISC. Mucosal breaks are
not seen in small bowel bacterial overgrowth, but bacterial over-
growth and or immunosuppressant drugs could be responsible for
the mild small intestinal inﬂammatory changes seen in some pa-
tients with AISC and PSC.
The combination of colitis and small bowelmucosal breaks in the pa-
tients with AISCmight represent CD. However, it is unusual to see histo-
pathological changes consistent with UC in Crohn's disease of the small
bowel. There is a case report of 4 patients with well established pan-
ulcerative colitis that had problematic diffuse upper small bowel inﬂam-
mation (Valdez et al., 2000) but this inﬂammation seems to be some-
what different in location to the damage we observed at capsule
enterosocpy and it is otherwise ﬁrmly accepted that patientswith ulcer-
ative have the disease conﬁned to the large bowel. Small bowel CD fre-
quently progresses to structuring requiring surgery, somethingwhich is
not in evidence clinically (Gregorio et al., 2001) nor as evidenced by the
capsule enteroscopy results in AISC.
Further points of distinction between the colitis of IBD and PSC
(data on AISC is lacking) are the differences in the prevalence of
pouchitis after restorative ileo-anal (rectal) pouch anastomosis
after colectomy, being 2–3 times higher in PSC than UC (Pavlides
et al., 2014) and quite comparable if not higher than that in CD
(Achkar and Shen, 2001). Lastly genome wide association studies
have identiﬁed a number of susceptibility genes in IBD and PSC, but
most of these differ signiﬁcantly between the two groups of patients
(Eaton et al., 2013).
In conclusion, collectively our ﬁndings and previous studies suggest
that the colitis associated with PSC, and AISC is distinctively different
from classical IBD. Furthermore, the small bowel mucosal breaks in
AISC are incompatible with a diagnosis of UC. These ﬁndings reinforce
the idea that the inﬂammatory bowel disease associated with AISC
and PSC should be considered as distinct nosologic entities separate
from UC and CD, namely chronic IBD associated with chronic liver
disease.
Fig. 1. a: A representative capsule enteroscopy ileal image from a normal subject. b: A capsule enteroscopy ileal image demonstrating a linear mucosal break in a patient with AISC. c: A
capsule enteroscopy ileal image demonstrating an aphthous like mucosal break in a patient with AISC. d: A capsule enteroscopy ileal image demonstrating two linearmucosal breaks in a
patient with AISC.
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